Werewolf Therapeutics, Inc. (HOWL): Price and Financial Metrics
HOWL Price/Volume Stats
| Current price | $1.29 | 52-week high | $4.18 |
| Prev. close | $1.23 | 52-week low | $0.60 |
| Day low | $1.22 | Volume | 516,500 |
| Day high | $1.31 | Avg. volume | 361,561 |
| 50-day MA | $1.00 | Dividend yield | N/A |
| 200-day MA | $1.57 | Market Cap | 57.89M |
HOWL Stock Price Chart Interactive Chart >
Werewolf Therapeutics, Inc. (HOWL) Company Bio
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It offers PREDATOR, a platform of protein engineering technology to design and engineer the future of immuno-oncology biotherapeutics for patients. The company's lead product candidates include WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. It also develops WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
HOWL Price Returns
| 1-mo | 30.30% |
| 3-mo | 7.50% |
| 6-mo | -21.82% |
| 1-year | -60.31% |
| 3-year | -72.55% |
| 5-year | N/A |
| YTD | -12.84% |
| 2024 | -61.66% |
| 2023 | 88.29% |
| 2022 | -82.79% |
| 2021 | N/A |
| 2020 | N/A |
Loading social stream, please wait...